• Agreement covers 11 clinical locations across Pennsylvania and New Jersey
• Includes two immediate Technegas installations at top-ranked hospitals
• Potential for expansion to additional UPHS-affiliated sites

Cyclopharm Limited (ASX: CYC) has announced a multi-site agreement with the University of Pennsylvania Health System (UPHS), covering 11 clinical locations across Pennsylvania and New Jersey in the United States. The agreement provides for two immediate Technegas installations at the Hospital of the University of Pennsylvania and the Perelman Center for Advanced Medicine, as well as contracted installations across a further nine sites in the UPHS network over time. The agreement also includes potential for expansion beyond the contracted 11 locations to additional sites affiliated with UPHS. The Hospital of the University of Pennsylvania is a top 20 hospital in the US and the leading hospital in Pennsylvania. The UPHS agreement represents a major milestone for Cyclopharm's US commercial rollout, providing scale, near-term revenue initiation, a recurring revenue profile, and an expansion pathway. Consistent with Cyclopharm's commercial model, revenue will be driven by a combination of installation, annual support, and recurring per-patient consumables usage. The multi-site nature of this agreement is another example of Cyclopharm's strategy to progress from initial installations to system-wide adoption within large US healthcare networks and Independent Delivery Networks.

This agreement further demonstrates the accelerating execution of Cyclopharm's US strategy, which is focused on establishing leading reference sites, building regional density, and expanding across large integrated delivery networks.